SecBot SecBot
PRESS-RELEASE ·Filed Mar 28, 2026

KYMR

Kymera Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming Phase 2b data readouts as key catalysts; positive results could validate KT-621 as a best-in-class oral therapy for Type 2 inflammation, supporting premium valuation ahead of pivotal trials.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.48
T+0 close · Mar 28, 2026 · via day close
Latest settled
+46.53%
T+60 · $116.46
Vs SPY
+30.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $79.48entry
  2. T+1 · 8mo ago +4.79%α +1.90% · $83.29
  3. T+5 · 7mo ago +7.07%α +2.77% · $85.10
  4. T+20 · 7mo ago +5.50%α −7.10% · $83.85
  5. T+60 · 5mo ago +46.53%α +30.04% · $116.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kymera Therapeutics announced positive Phase 1b trial results for KT-621, an oral STAT6 degrader, showing deep target degradation and encouraging clinical activity in patients with moderate-to-severe atopic dermatitis. The data support further development in ongoing Phase 2b trials, with readouts expected by mid-2027 and late-2027.

Key Facts

  • KT-621 demonstrated 94% median STAT6 degradation in skin and 98% in blood after 28 days of dosing.
  • Robust biomarker reductions: 74% median TARC reduction, up to 73% Eotaxin-3, 56% IL-31, and 14% IgE.
  • Clinical improvements: 63% mean EASI reduction, 29% achieved EASI-75, 19% reached vIGA-AD 0/1, 40% peak pruritus NRS reduction.
  • KT-621 was well tolerated with a favorable safety profile.
  • Phase 2b trials (BROADEN2 in AD, BREADTH in asthma) ongoing; data expected mid-2027 and late-2027.

Financial Impact

No direct financial impact reported; potential long-term value creation if Phase 2b trials confirm efficacy.

pipeline_valueR_and_D_expensemarket_sentiment

Risk Factors

  • Phase 1b results may not be predictive of Phase 2b or Phase 3 outcomes.
  • Competition from established biologics (e.g., dupilumab) and emerging oral agents in atopic dermatitis.
  • Dilution risk from future capital raises to fund advancing clinical programs.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264183

Track record

37 reports on KYMR

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 28, 2026